The capital infusion arrives as the company targets broader adoption of its TMINI platform, which currently maintains compatibility with roughly 70% of the total knee implant market. According to CEO Stuart Simpson, this liquidity, bolstered by recent support from existing backers, provides a clear runway for the firm to reach sustained profitability.

Symbiotic Capital’s Senior Managing Director, Himani Bhalla, pointed to the system’s value proposition for both surgeons and patients as a primary driver for the investment. By positioning its technology as an open platform that supports various implant brands, THINK Surgical continues to differentiate itself from competitors that lock users into proprietary systems. Piper Sandler acted as the financial advisor during the transaction.